The de Morton mobility index is a feasible and valid mobility assessment tool in hospitalized patients with an acute exacerbation of chronic obstructive pulmonary disease.

There is no accepted standard for measuring mobility in hospitalized patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The objective of this study was to assess convergent, discriminant, and known-group validity and floor/ceiling effects of the de Morton Mobility Index (DEMMI) in hospitalized patients with AECOPD. Individuals with AECOPD (n = 22) admitted to an acute care hospital medical ward were recruited. Data on the DEMMI, gait speed, daytime energy expenditure, step counts, 6-minute walk distance (6MWD), dyspnea, respiratory and heart rates, quality of life, and oxygen supplementation were collected on day 3 of admission. The DEMMI demonstrated convergent validity with the 6MWD and gait velocity measures (Spearman's ρ 0.69 and 0.61, respectively; p < 0.003) but not with measures of physical activity or respiratory impairment. Discriminant validity was present, with no correlation between the DEMMI and quality of life and resting heart rate. Known-group validity (gait aids vs. no gait aids) was demonstrated (p = 0.009). There was no floor effect but there was evidence of a possible ceiling effect (14% of participants received a perfect score). The DEMMI is feasible and showed moderate to strong validity with measures of observed physical function in hospitalized patients with AECOPD.

Physical Activity Measurement Accuracy in Individuals With Chronic Lung Disease: A Systematic Review With Meta-Analysis of Method Comparison Studies.

OBJECTIVE: To investigate the accuracy of physical activity measurement strategies in adults with chronic lung disease. DATA SOURCES: MEDLINE, Embase, and CINAHL databases were searched from inception to September 30, 2014. STUDY SELECTION: Studies reporting validity data for devices measuring energy expenditure in comparison with indirect calorimetry or doubly labeled water measurements in chronic lung disease were included. Nine publications in chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF) from 2294 studies were identified. DATA EXTRACTION: Two reviewers evaluated studies for quality using a modified version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist and extracted data relating to population, setting, devices, activity protocols, and energy expenditure. Disagreements were resolved by consensus. DATA SYNTHESIS: Studies were of high quality, with 8 studies scoring at least 9 out of 11 on the QUADAS checklist. In laboratory-based settings, the SenseWear multisensor accurately estimated energy expenditure during walking compared with indirect calorimetry (pooled mean difference, -0.7 kcal/min; 95% confidence interval [CI], -2.5 to 1.1) in COPD, but overestimated it in CF. However, 2 studies in COPD and CF showed the SenseWear multisensor accurately estimated energy expenditure during lifestyle tasks compared with indirect calorimetry (pooled mean difference, .18 kcal/min; 95% CI, -.13 to .49). The Digi-Walker pedometer underestimated energy expenditure compared with indirect calorimetry in COPD (mean difference walking, -2.4 kcal/min; 95% CI -3.4 to -1.1; mean difference lifestyle tasks, -2.3 kcal/min; 95% CI, -2.8 to -1.8). In free-living settings, the ActiReg multisensor accurately measured energy expenditure in COPD (mean difference, -21 kcal/d; 95% CI, -133.9 to 91.9), whereas the Flex Heart Rate Method underestimated energy expenditure in CF (mean difference, -454.1 kcal/d; 95% CI, -727 to -181.2). CONCLUSIONS: Energy expenditure estimation was accurate from the SenseWear and ActiReg multisensors during laboratory-based and free-living testing. Future studies warrant investigation of activity measures in other lung diseases and in specific ranges of lung disease severity.

[Efficiency of seasonal influenza vaccine in persons older than 65 in Romania. Pilot case-control study I-MOVE, 2008-2009]. / Eficacitatea vaccinului gripal sezonier la persoanele cu vârsta peste 65 de ani din România. Studiul pilot caz-martor I-MOVE, 2008-2009.

Cantacuzino Institute conducted between September 2008 and June 2009, a pilot case-control study to monitor the influenza vaccine effectiveness on people over 65 years of age from Romania. This study is part of the I-MOVE project "Monitoring the vaccine effectiveness during seasonal and pandemic influenza in EU/EEA member states, 2008-2009", coordinated by EpiConcept, France and financed by European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. Forty seven family doctors and epidemiologists from Bucharest and seven influenza sentinel districts were selected to participate in this project, based on epidemiological and geographical criteria. Family doctors swabbed all people over 65-years-old consulting for influenza like illness (ILI). Influenza confirmed cases (classified as cases) were compared to influenza negative controls. Influenza vaccine effectiveness (IVE) was obtained using the formula: 1 - odds ratio, with 95% confidence interval (CI). One hundred and three ILI patients were enrolled in the study. Ninety nine from them (96.1%) were swabbed in the first 7 days after the onset, met the inclusion criteria and case definition and were included in analysis. Thirty (30.3%) were ILI flu positive and were classified as cases, sixty nine (69.7%) were ILI flu negative and classified as controls. Influenza vaccine effectiveness adjusted for the predefined set of confounders (age, sex, chronic diseases, smoking, previous influenza vaccination, functional status) was 86.8% (95% CI, 38.0, 97.2); influenza vaccine coverage in people older than 65 years was 49.4%. The result of the study showed a high influenza vaccine effectiveness in the elderly. In order to achieve a greater precision, the national and also the European samples should be extended for the next season.

Myocardial Infarction Injury in Patients with Chronic Lung Disease Entering Pulmonary Rehabilitation: Frequency and Association with Heart Rate Parameters.

BACKGROUND: Myocardial infarction (MI) remains under-recognized in chronic lung disease (CLD) patients. Rehabilitation health professionals need accessible clinical measurements to identify the presence of prior MI in order to determine appropriate training prescription. OBJECTIVES: To estimate prior MI in CLD patients entering a pulmonary rehabilitation program, as well as its association with heart rate parameters such as resting heart rate and chronotropic response index. DESIGN: Retrospective cohort design. SETTING: Pulmonary rehabilitation outpatient clinic in a tertiary care university-affiliated hospital. PATIENTS: Eighty-five CLD patients were studied. METHODS: Electrocardiograms at rest and peak cardiopulmonary exercise testing, performed before pulmonary rehabilitation, were analyzed. Electrocardiographic evidence of prior MI, quantified by the Cardiac Infarction Injury Score (CIIS), was contrasted with reported myocardial events and then correlated with resting heart rate and chronotropic response index parameters. MAIN OUTCOME MEASUREMENTS: CIIS, resting heart rate, and chronotropic response index. RESULTS: Sixteen CLD patients (19%) demonstrated electrocardiographic evidence of prior MI, but less than half (8%) had a reported MI history (P < .05). The Cohen's kappa test revealed poor level of agreement between CIIS and medical records (kappa = 0.165), indicating that prior MI diagnosis was under-reported in the medical records. Simple and multiple regression analyses showed that resting heart rate but not chronotropic response index was positively associated with CIIS in our population (R2 = 0.29, P < .001). CLD patients with a resting heart rate higher than 80 beats/min had approximately 5 times higher odds of having prior MI, as evidenced by a CIIS ≥ 20. CONCLUSIONS: CLD patients entering pulmonary rehabilitation are at risk of unreported prior MI. Elevated resting heart rate appears to be an indicator of prior MI in CLD patients; therefore, careful adjustment of training intensity is recommended under these circumstances. LEVEL OF EVIDENCE: III.